logo

For the Inventor, By the Inventor

Chita, Japan

Nobuji Yoshikawa

This inventor holds 8 USPTO granted patents. Top assignee: Pfizer Corporation. Active years: 1999-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nobuji Yoshikawa. Retrieved from https://idiyas.com/inventor/nobuji-yoshikawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8

% Patents Active = 100.0

Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 15(Granted Patents)


Location History:

  • Aichi-ken, JP (2000 - 2001)
  • Nagoya, JP (2001)
  • Anjo, JP (1999 - 2002)
  • Chita-gun, JP (2002)

Company Filing History:

goldMedal8 out of 4,488 
 
Pfizer Corporation
 patents

Years Active: 1999-2002

Loading Chart...
8 patents (USPTO):Explore Patents
1. 6416979 - 5-substituted picolinic acid compounds production by Marasmiellus sp (2002-07-09),
2. 6391616 - Oidiodendron strain for the production of terpenoid lactone compounds (2002-05-21),
3. 6277860 - Furopyridine antibacterials (2001-08-21),
4. 6225339 - Terpenoid lactone compounds and their production process (2001-05-01),
5. 6221899 - Terpenoid lactone compounds and their production process (2001-04-24),
6. 6194442 - 5-substituted picolinic acid compounds and their method of use (2001-02-27),
7. 6034107 - 5-Substituted picolinic acid compounds and their production process (2000-03-07),
8. 5885959 - Cyclic peptide compounds and their production process (1999-03-23),

Title: Nobuji Yoshikawa: Innovator in Terpenoid Lactone Compounds

Introduction

Nobuji Yoshikawa is a prominent inventor based in Chita, Japan. He has made significant contributions to the field of pharmaceutical compounds, particularly in the production of terpenoid lactone compounds. With a total of 8 patents to his name, Yoshikawa's work has garnered attention in the scientific community.

Latest Patents

One of his latest patents involves the production of 5-substituted picolinic acid compounds by utilizing Marasmiellus sp - Oidiodendron strain. This innovative process allows for the cultivation of FERM BP-5778, followed by the isolation of terpenoid lactone compounds from the fermentation broth. The invention also includes a pharmaceutical composition that features the terpenoid lactone compound, which is beneficial in treating IL-1 and TNF mediated diseases.

Career Highlights

Yoshikawa is currently associated with Pfizer Corporation, where he continues to advance his research and development efforts. His work has not only contributed to the company's portfolio but has also played a crucial role in the advancement of pharmaceutical sciences.

Collaborations

Throughout his career, Yoshikawa has collaborated with notable colleagues, including Nakao Kojima and Hiroyuki Nishida. These partnerships have facilitated the exchange of ideas and have led to further innovations in their respective fields.

Conclusion

Nobuji Yoshikawa's contributions to the field of terpenoid lactone compounds exemplify the impact of innovative research in pharmaceuticals. His ongoing work at Pfizer Corporation continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…